AndhraNews.net
Home » Business News » 2013 » June » June 24, 2013

Actavis Launches Generic Viagra(R) in Europe as Patents Expire


June 24, 2013 - Zug, Switzerland

Actavis, Inc. (NYSE: ACT), a leadingglobal specialty pharmaceutical company, today announced that it haslaunched Sildenafil Actavis 25 mg, 50 mg and 100 mg tablets in 11 majorWestern-European markets on market formation. Sildenafil Actavis, thegeneric equivalent of Pfizer's Viagra®, is prescribed to treaterectile dysfunction.

Actavis' product was launched immediately after the patents expired inAustria, Denmark, France, Germany, Ireland, Italy, The Netherlands, Spain,Sweden, Switzerland and the United Kingdom.

Actavis first launched Sildenafil tablets in Bulgaria in June 2009 - thefirst generic Sildenafil to enter the patent-free Bulgarian market - andhas since launched the product in various other patent-free markets inEurope, including Iceland and Malta. Sildenafil Actavis is manufacturedand developed by Actavis, in Malta and Iceland respectively.

According to IMS Health, Viagra® had sales of EUR382.2 million inEurope for the 12 months ending March 31, 2013.

About Actavis

Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceuticalcompany focused on developing, manufacturing and distributing generic,brand and biosimilar products. Actavis has global headquarters inParsippany, New Jersey, USA.

Operating as Actavis Pharma, Actavis develops, manufactures and marketsgeneric, branded generic, legacy brands and Over-the-Counter (OTC) productsin more than 60 countries.

Actavis Specialty Brands is Actavis' global branded specialtypharmaceutical business focused in the Urology and Women's Healththerapeutic categories. Actavis Specialty Brands also has a portfolio offive biosimilar products in development in Women's Health and Oncology.Actavis Global Operations has more than 30 manufacturing and distributionfacilities around the world, and includes Anda, Inc., a U.S. pharmaceuticalproduct distributor.

For press release and other company information, visit Actavis' Web site atwww.actavis.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historicalfacts are forward-looking statements that reflect Actavis' currentperspective of existing information as of the date of this release. It isimportant to note that Actavis' goals and expectations are not predictionsof actual performance. Actual results may differ materially from Actavis'current expectations depending upon a number of factors, risks anduncertainties affecting Actavis' business. These factors include, amongothers, the impact of competitive products and pricing; the timing andsuccess of product launches; difficulties or delays in manufacturing; theavailability and pricing of third party sourced products and materials;successful compliance with governmental laws, rules and regulationsapplicable to Actavis and its third party manufacturers' facilities,products and/or businesses; changes in the laws and regulations affectingamong other things, pricing and reimbursement of pharmaceutical products;and such other risks and uncertainties detailed in Actavis' periodic publicfilings with the Securities and Exchange Commission, including but notlimiting to Actavis' Quarterly Report on Form 10-Q for the quarter endedMarch 31, 2013 and Actavis' annual report on Form 10-K for the year endedDecember 31, 2012. Except as expressly required by law, Actavis disclaimsany intent or obligation to update these forward-looking statements.

Viagra® is a registered trademark of Pfizer, Inc.

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Actavis via Thomson Reuters ONE

[HUG#1711439]

CONTACTS:
Investors:
Lisa DeFrancesco
+1 862 261 7152

Media:
Elisabet Hjaltadottir
+41 79 909 7370

MarketWire

Comment on this story

Share